vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and TOOTSIE ROLL INDUSTRIES INC (TR). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $196.3M, roughly 1.3× TOOTSIE ROLL INDUSTRIES INC). TOOTSIE ROLL INDUSTRIES INC runs the higher net margin — 14.7% vs 11.1%, a 3.5% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 1.5%). TOOTSIE ROLL INDUSTRIES INC produced more free cash flow last quarter ($61.0M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 13.2%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Tootsie Roll Industries is an American manufacturer of confectionery based in Chicago, Illinois. Its best-known products include the namesake Tootsie Rolls and Tootsie Pops. Tootsie Roll Industries currently markets its brands internationally in Canada, Mexico, and over 75 other countries.
ANIP vs TR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $196.3M |
| Net Profit | $27.5M | $28.8M |
| Gross Margin | — | 35.7% |
| Operating Margin | 14.1% | 17.0% |
| Net Margin | 11.1% | 14.7% |
| Revenue YoY | 29.6% | 1.5% |
| Net Profit YoY | 367.5% | 27.9% |
| EPS (diluted) | $1.14 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $196.3M | ||
| Q3 25 | $227.8M | $232.7M | ||
| Q2 25 | $211.4M | $155.1M | ||
| Q1 25 | $197.1M | $148.5M | ||
| Q4 24 | $190.6M | $193.4M | ||
| Q3 24 | $148.3M | $225.9M | ||
| Q2 24 | $138.0M | $150.7M | ||
| Q1 24 | $137.4M | $153.2M |
| Q4 25 | $27.5M | $28.8M | ||
| Q3 25 | $26.6M | $35.7M | ||
| Q2 25 | $8.5M | $17.5M | ||
| Q1 25 | $15.7M | $18.1M | ||
| Q4 24 | $-10.3M | $22.5M | ||
| Q3 24 | $-24.2M | $32.8M | ||
| Q2 24 | $-2.3M | $15.6M | ||
| Q1 24 | $18.2M | $15.8M |
| Q4 25 | — | 35.7% | ||
| Q3 25 | — | 34.1% | ||
| Q2 25 | — | 36.4% | ||
| Q1 25 | — | 35.3% | ||
| Q4 24 | — | 39.1% | ||
| Q3 24 | — | 34.1% | ||
| Q2 24 | — | 33.5% | ||
| Q1 24 | — | 32.7% |
| Q4 25 | 14.1% | 17.0% | ||
| Q3 25 | 15.9% | 13.9% | ||
| Q2 25 | 6.6% | 7.8% | ||
| Q1 25 | 13.3% | 15.5% | ||
| Q4 24 | -2.3% | 20.0% | ||
| Q3 24 | -13.8% | 15.6% | ||
| Q2 24 | 3.7% | 10.2% | ||
| Q1 24 | 14.8% | 7.3% |
| Q4 25 | 11.1% | 14.7% | ||
| Q3 25 | 11.7% | 15.3% | ||
| Q2 25 | 4.0% | 11.3% | ||
| Q1 25 | 8.0% | 12.2% | ||
| Q4 24 | -5.4% | 11.6% | ||
| Q3 24 | -16.3% | 14.5% | ||
| Q2 24 | -1.7% | 10.4% | ||
| Q1 24 | 13.2% | 10.3% |
| Q4 25 | $1.14 | — | ||
| Q3 25 | $1.13 | — | ||
| Q2 25 | $0.36 | — | ||
| Q1 25 | $0.69 | — | ||
| Q4 24 | $-0.45 | — | ||
| Q3 24 | $-1.27 | — | ||
| Q2 24 | $-0.14 | — | ||
| Q1 24 | $0.82 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $176.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $941.0M |
| Total Assets | $1.4B | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $176.6M | ||
| Q3 25 | $262.6M | $119.8M | ||
| Q2 25 | $217.8M | $170.5M | ||
| Q1 25 | $149.8M | $176.6M | ||
| Q4 24 | $144.9M | $194.6M | ||
| Q3 24 | $145.0M | $163.2M | ||
| Q2 24 | $240.1M | $131.2M | ||
| Q1 24 | $228.6M | $159.4M |
| Q4 25 | $540.7M | $941.0M | ||
| Q3 25 | $505.8M | $918.9M | ||
| Q2 25 | $436.8M | $893.1M | ||
| Q1 25 | $418.6M | $879.4M | ||
| Q4 24 | $403.7M | $870.7M | ||
| Q3 24 | $405.9M | $870.2M | ||
| Q2 24 | $455.8M | $841.4M | ||
| Q1 24 | $452.0M | $834.4M |
| Q4 25 | $1.4B | $1.3B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.3B | $1.1B | ||
| Q4 24 | $1.3B | $1.1B | ||
| Q3 24 | $1.3B | $1.1B | ||
| Q2 24 | $920.8M | $1.1B | ||
| Q1 24 | $914.5M | $1.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $73.3M |
| Free Cash FlowOCF − Capex | $29.1M | $61.0M |
| FCF MarginFCF / Revenue | 11.8% | 31.1% |
| Capex IntensityCapex / Revenue | 0.5% | 6.3% |
| Cash ConversionOCF / Net Profit | 1.10× | 2.55× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $96.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $73.3M | ||
| Q3 25 | $44.1M | $62.2M | ||
| Q2 25 | $75.8M | $-8.5M | ||
| Q1 25 | $35.0M | $3.6M | ||
| Q4 24 | $15.9M | $68.8M | ||
| Q3 24 | $12.5M | $61.3M | ||
| Q2 24 | $17.4M | $-12.6M | ||
| Q1 24 | $18.3M | $21.4M |
| Q4 25 | $29.1M | $61.0M | ||
| Q3 25 | $38.0M | $50.7M | ||
| Q2 25 | $71.8M | $-16.0M | ||
| Q1 25 | $32.5M | $750.0K | ||
| Q4 24 | $13.5M | $64.7M | ||
| Q3 24 | $7.7M | $55.8M | ||
| Q2 24 | $13.0M | $-16.6M | ||
| Q1 24 | $13.7M | $16.9M |
| Q4 25 | 11.8% | 31.1% | ||
| Q3 25 | 16.7% | 21.8% | ||
| Q2 25 | 34.0% | -10.3% | ||
| Q1 25 | 16.5% | 0.5% | ||
| Q4 24 | 7.1% | 33.5% | ||
| Q3 24 | 5.2% | 24.7% | ||
| Q2 24 | 9.4% | -11.0% | ||
| Q1 24 | 10.0% | 11.0% |
| Q4 25 | 0.5% | 6.3% | ||
| Q3 25 | 2.7% | 5.0% | ||
| Q2 25 | 1.9% | 4.8% | ||
| Q1 25 | 1.3% | 1.9% | ||
| Q4 24 | 1.3% | 2.1% | ||
| Q3 24 | 3.2% | 2.4% | ||
| Q2 24 | 3.2% | 2.6% | ||
| Q1 24 | 3.3% | 2.9% |
| Q4 25 | 1.10× | 2.55× | ||
| Q3 25 | 1.66× | 1.74× | ||
| Q2 25 | 8.87× | -0.49× | ||
| Q1 25 | 2.23× | 0.20× | ||
| Q4 24 | — | 3.06× | ||
| Q3 24 | — | 1.87× | ||
| Q2 24 | — | -0.81× | ||
| Q1 24 | 1.00× | 1.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
TR
| Products | $194.3M | 99% |
| Rental And Royalty | $1.9M | 1% |
